Intercept Pharmaceuticals, Inc. (ICPT): Price and Financial Metrics

Intercept Pharmaceuticals, Inc. (ICPT): $19.00

0.04 (+0.21%)

POWR Rating

Component Grades








Add ICPT to Watchlist
Sign Up

Industry: Biotech




#32 of 351

in industry

ICPT Price/Volume Stats

Current price $19.00 52-week high $21.86
Prev. close $18.96 52-week low $8.82
Day low $18.98 Volume 3,963,400
Day high $19.01 Avg. volume 1,362,029
50-day MA $15.82 Dividend yield N/A
200-day MA $14.74 Market Cap 793.88M

ICPT Stock Price Chart Interactive Chart >

Intercept Pharmaceuticals, Inc. (ICPT) Company Bio

Intercept Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic underserved liver diseases. The company was founded in 2002 and is based in New York, New York.

ICPT Latest News Stream

Event/Time News Detail
Loading, please wait...

ICPT Latest Social Stream

Loading social stream, please wait...

View Full ICPT Social Stream

Latest ICPT News From Around the Web

Below are the latest news stories about INTERCEPT PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ICPT as an investment opportunity.

Will Intercept Pharmaceuticals (ICPT) Report Negative Q3 Earnings? What You Should Know

Intercept (ICPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | October 31, 2023

Stocks to Sell: 7 Overbought Companies You Ought to Dump Right Now

Overbought stocks are an early indication of a potential correction on a stock; act now if you hold these stocks.

Rick Orford on InvestorPlace | October 19, 2023

Intercept Pharmaceuticals (NASDAQ:ICPT) shareholders have endured a 83% loss from investing in the stock five years ago

It is a pleasure to report that the Intercept Pharmaceuticals, Inc. ( NASDAQ:ICPT ) is up 67% in the last quarter. But...

Yahoo | October 11, 2023

Madrigal (MDGL) to Raise Capital Via Public Offering of $500M

Madrigal (MDGL) is raising funds through a public offering of 1.25 million shares of its common stock to use in commercial activities in the preparation of a potential launch of resmetirom in the United States.

Yahoo | October 2, 2023

Biotech Stock Roundup: ICPT Up on Buyout Deal, IMVT & PLRX Gain on Study Data

Acquisition news from Intercept (ICPT) and study updates from Immunovant (IMVT) are in focus in the biotech sector.

Yahoo | September 28, 2023

Read More 'ICPT' Stories Here

ICPT Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year 76.42%
3-year 14.25%
5-year -77.06%
2023 0.00%
2022 -24.06%
2021 -34.05%
2020 -80.07%
2019 22.95%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!